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Potassium channel blockers are sometimes eﬀective in the rhythm management of
persistent atrial ﬁbrillation. However, on rare occasions, a life-threatening episode of torsade
de pointes develops during treatment with these agents. Among several precautions against
this tragedy, preventing exaggerated QT prolongation is of paramount importance. One of the
diﬃculties in monitoring the QT interval during atrial ﬁbrillation is the fact that its length
varies depending not only on the ﬂuctuating preceding intervals, but on other factors such as
neurohumoral activation. In fact, even at the same preceding RR interval, the QT interval may
vary from day to night, between atrial ﬁbrillation and sinus rhythm. Accordingly, the QTc
interval may not be a reliable parameter for predicting proarrhythmic events. As the result,
close monitoring of the QT interval itself, just like INR monitoring during warfarin treatment,
is mandatory both before and during treatment with these agents.
(J Arrhythmia 2010; 26: 5–15)
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Sunny and dark sides of pharmacologic rhythm
management of atrial ﬁbrillation
Atrial ﬁbrillation (AF) remains a challenging
arrhythmia despite signiﬁcant progress being made
in suppression of this arrhythmia both pharmacolog-
ically and nonpharmacologically. Acute AF is often
successfully suppressed with various Na channel
blockers,1) and if it is repetitive and symptomatic,
pulmonary vein isolation with radiofrequency abla-
tion is becoming a powerful option in eliminating
this arrhythmia. In contrast, when AF persists longer
and electrical remodeling develops, pharmacological
rate control of this arrhythmia is sometimes pre-
ferred.1,2) One of the reasons for favoring the
conservative approach to persistent AF is that, as
atrial electrical remodeling progresses, the anti-AF
eﬃcacy of Na channel blockers wanes,3,4) making
rhythm management more diﬃcult. On the other
hand, some of the K channel blockers such as
amiodarone, sotalol, or dofetilide have been reported
to be eﬀective in terminating such persistent AF,
although their conversion rates were unimpressive
at less than 30%.5–7) Notably, 1 to 2 months of daily
administration of bepridil, an IKr and other multi-
channel blocker, has demonstrated surprisingly
high eﬃcacies of 58 to 69% in terminating per-
sistent AF,8,9) and its clinical use has recently
been approved in Japan for the indication of
pharmacologic rhythm management of persistent
AF.
This recommendation, however, is not straightfor-
ward, and needs to accompany a warning to those
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who plan to prescribe such K channel blockers for
this purpose. One should be aware that most of these
agents exert their action on myocardial cells of both
the atrium and the ventricle. While the eﬀect of
prolongation of the atrial refractory period by the
drug may be antiarrhythmic and beneﬁcial, the same
or even exaggerated eﬀect on the ventricle can be
proarrhythmic and unwanted. The result of the latter
is torsade de pointes (TdP), a notorious life-threat-
ening arrhythmia with a characteristic electrocardio-
graphic manifestation associated with prolonged
ventricular repolarizaton. This proarrhythmic eﬀect
of K channel blockers has been seen not only in the
treatment of ventricular tachyarrhythmias, but also
in the treatment of supraventricular tachyarrhyth-
mias,10,11) a more unexpected and less desirable
result. For example, in a multicenter, double-blind,
placebo-controlled, dose-ranging study of dofetilide
called SAFIRE-D, 3 proarrhythmic events leading to
ventricular ﬁbrillation including 1 fatal case occur-
red in 241 patients receiving diﬀerent doses of
dofetilide.7) In another multicenter, double-blind,
placebo-controlled, dose-ranging study in Japan
called J-BAF which comprised 90 patients with
persistent atrial ﬁbrillation, 1 patient died of proar-
rhythmic eﬀect of bepridil within three months of
follow-up.12) The treatment should not be worse than
the disease itself. However, the prevention of TdP in
this particular setting of atrial ﬁbrillation is some-
times complicated and diﬃcult as will be discussed
subsequently.
Precipitating factors for TdP
TdP is caused by abnormal automaticity and
subsequent reentrant arrhythmias in an electrophy-
siological substrate of markedly prolonged and
dispersed repolarization of myocardial cells. The
initiating automatic activity, or triggered activity, is
the result of early afterdepolarization, which char-
acteristically develops during the phase 3 of the
action potential only when its duration is abnormally
prolonged13,14) (Figure 1). The prolongation of the
action potential can often be brought by inhibiting
outward currents. Therefore, those agents blocking
outward K currents, which theoretically prolong the
refractory period of myocardial cells and is expected
to prevent reenty, are at the same time a typical
culprit responsible for this proarrhythmic phenom-
enon.
We have long intended to avoid this tragic
complication during the treatment with K channel
blockers in various ways. The blockade of K
currents with these agents is apparently dependent
on its concentration. Therefore, it is a matter of
course to limit the dose of these agents after
considering the body weight and age as well as
liver and renal functions of the patient. It may be
better to withhold the administration of these agents
to those in whom the baseline duration of the action
potential is prolonged due to congenitally defective
genes regulating the action potential (long QT
syndrome) or adjust the dose in similar patients
with acquired defective genes encoding the K
channel, such as those developing heart failure.15)
Caution should be exercised when prescribing these
agents to female patients who are known to be more
susceptible to TdP than male patients, a diﬀerence
most likely related to gender-speciﬁc hormones.16)
In addition, since the action potential duration
increases as the serum potassium becomes lower,
the proarrhythmic adverse events with K channel
blockers occur more frequently in the presence of
hypopotassemia as is often the case during treatment
with diuretics.17) It has been suggested that the serum
potassium level should always be kept above
4.0mEq/L. Drug-to-drug interaction is always a
matter of concern. It is not unusual for a patient to
receive a new drug for noncardiac diseases from
another doctor.
It will be helpful to check these risk factors for
TdP systematically both before and after the treat-
ment with K channel blockers has been instituted.
These factors can easily be memorized by alphabet
acronyms as listed in Table 1.
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Figure 1 Quinidine-induced early afterdepolarization
(Adopted from 13)
Action potentials were recorded from a single canine Purkinje cell
at cycle lengths from 1,000 to 8,000msec.
Note the action potential duration increased as the cycle length
was increased to the critical point when early afterdepolarization
developed during phase 3.
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QT interval as the key determinant of TdP
Even when all these precautions and recommen-
dation are taken into consideration by each pre-
scribing doctor, the prediction and prevention of
TdP remain diﬃcult. As the response of the
myocardial cells to K channel blockers is quite
variable and sometimes unpredictable, all we need
is to monitor the patient carefully, sometimes
continuously, sometimes repeatedly. No doubt the
most important parameter to monitor is the QT
interval on the surface electrocardiogram, which
reﬂects summation of the action potential duration
of the ventricular myocardial cells. It is at the same
time, a marker for the degree of K channel
blockade.
If one is treating supraventricular arrhythmias
with K channel blockers, QT prolonagation is not a
requisite since the target for prolongation of action
potential duration is not the ventricular cells but the
atrial cells whose action potential duration is neither
apparent nor reﬂected on the surface electrocardio-
gram. On the other hand, QT prolongation is not
only a marker for antiarrhythmic eﬀect of K channel
blockers against ventricular arrhythmias, but more
importantly a marker for the risk of developing TdP
in any clinical settings.
In a case-control study comparing 30 cases of
bradyarrhythmias complicated by TdP with 113
cases of uncomplicated bradyarrhythmias, cutoﬀ
value for the QT interval that distinguished the
former from the latter was 570msec with 90.0%
sensitivity and 86.7% speciﬁcity.18) In another single
center survey of 459 patients receiving bepridil for
the treatment of AF or ﬂutter, Yasuda et al have
reported that TdP developed in 4 patients during an
average follow up of 20 months.19) In addition to the
fact that 3 of them had structural heart disease, all
4 had hypopotassemia with serum K levels 3.8
mEq/L or lower. QT intervals before developing
TdP were consistently 0.56 sec or longer.
Monitoring the QT interval is not just recom-
mended but is mandatory each time a K channel
blocker is prescribed for the treatment of arrhyth-
mias, whether supraventricular or ventricular. How-
ever, monitoring the QT interval during AF is, unlike
that during sinus rhythm, much more challenging. It
is true that it is sometimes diﬃcult to precisely
measure the QT interval in the presence of ﬁne
waves of AF. The automatic measurement of QT
intervals using a computer lacks reliability partic-
ularly during AF. However, the problem with AF is
far more complicated.
Variable QT intervals during AF
Even in a single subject and at a constant serum
potassium level, the action potential duration and the
QT interval vary substantially within a day. Charac-
teristically, the QT interval prolongs when the heart
rate is slow as during the night, and shortens as the
heart rate becomes faster as during activities in the
daytime. This phenomenon is seen even in patients
without K channel blockers. Notably, however, when
a K channel blocker is administered, this pattern of
reverse rate dependency (the faster the rate, the less
K channel blockade) gets magniﬁed,20) so that a
marked prolongation of QT interval becomes appa-
rent sometimes during the night (Figure 2). This
pattern of reverse rate dependency has been reported
to be more signiﬁcant in the presence of structural
heart disease21) (Figure 3). It follows that the risk of
developing early afterdepolarization and TdP be-
comes higher during bradycardia18,22) particularly in
patients with structural heart disease. In a previously
cited series of Yasuda et al, heart rates were 48 or
less in all the 4 patients developing TdP.19)
Although bradycardia is typically seen during the
night, a long pause triggering TdP can also develop
in other situations. A long pause generated after
premature contractions sometimes gives rise to a
similar but transient milieu for developing TdP.
During AF, there are wide ﬂuctuations of the RR
interval, sometimes accompanying oscillatory short-
long-short cycle length patterns. These patterns are
known to set the stage for TdP even during the
daytime.23) The extreme of this condition is brought
when AF or atrial tachyarrhythmias convert into
sinus rhythm. After a prolonged sinus node suppres-
sion induced by rapid atria excitation, a substantially
long pause follows once the tachyarrhythmia termi-
nates, which may predispose the patient to TdP
(Figure 4). This phenomenon could even be accen-
tuated in the presence of sick sinus syndrome, which
at times is induced by antiarrhythmic drugs.
Table 1 Risk factors for TdP
A aged
B bradycardia
C cardiomyopathy
D drugs combined
E excessive dose
F female
G genetics
H hypopotassemia
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Since the longer the QT interval, the higher the
likelihood of developing TdP, ﬁnding the longest
QT interval after an intensive search for a single
complex preceded by the longest RR interval is
extremely important. It would be easy to understand
that the measurement of QT intervals on a routine
electrocardiogram of a short duration recorded in the
daytime in front of a doctor or technician wearing a
white lab coat may not be suﬃcient and may be
misleading. Obtaining a longer trace by using a
Holter monitoring is thus preferred for this purpose
even though there is a practical limitation as to how
often it should be recorded. With this technique,
however, it has been demonstrated that the develop-
ment of TdP was closely linked to the longest RR
intervals (Figure 5).
More complex behavior of QT intervals
It would be interesting to note that the RR interval
during treatment with K channel blockers is not a
single determinant of the QT interval and thus the
development of TdP. In a detailed analysis of the
relationship between the QT and RR intervals
preceding the onset of ventricular arrhythmias in a
patient with acquired prolongation of ventricular
repolarization, Gilmour et al have found that the QT
intervals were variable even if the immediately
HR 33/min
15:37  QT 0.42 sec
3:17  QT 0.72 sec
CH1
CH2
CH3
CH1
CH2
CH3
HR 71/min
Figure 2 QT intervals during day (top) and
night (bottom) in a patient receiving bepridil
A signiﬁcant QT prolongation was revealed
when the heart rate was decreased or SA block
developed during night.
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relationships based on
measurements from 24-hour Holter electro-
cardiograms (Adopted from 21)
The slope was larger in patients with structural
heart disease receiving bepridil (closed triangle,
0.57, n ¼ 14) than those in patients without
structural heart disease (open triangle, 0.34,
n ¼ 15) or control subjects not receiving bepri-
dil (open circle, 0.32, n ¼ 29) (p < 0:01).
p < 0:01 vs control subjects, p < 0:01 vs
patients without structural heart disease
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preceding RR intervals were similar24) (Figure 6).
They also demonstrated that the slope of the linear
relation between the RR and QT intervals was less
steep for the 10 intervals that preceded an episode of
ventricular arrhythmias than for earlier intervals
(Figure 7). In other words, the QT interval became
longest at any given RR interval just before the onset
of an episode of ventricular arrhythmias. The QT
interval was indeed a function not only of the
immediately preceding RR interval, but also of
previous RR intervals. In fact, it was dependent on
the cumulative eﬀect of the bradycardia that pre-
cedes an episode of ventricular arrhythmias and on
the tachycardia that occurs during the episode.
It is true that the TQ interval, the interval from the
end of T wave to the biginning of QRS complex
I
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V6
Figure 4 Pause-dependent initiation of
TdP
Note a marked QT prolongation in a sinus beat
following a pause after termination of atrial
tachyarrhythmia.
This patient was relatively stable on chronic
bepridil treatment until when tryptanol was
prescribed by a dermatologist for painful herpes
zoster infecton which precipitated this event.
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Figure 5 QT (top) and RR (bottom) inter-
vals during ambulatory ECG monitoring in a
patient with drug-induced QT prolongation
(Adopted from 24)
Episodes of ventricular arrhythmias including
TdP are indicated by the vertical lines.
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reﬂecting the excitable period of the ventricle, rather
than RR interval that aﬀects the QT interval of the
subsequent beat. Thus, even if the preceding RR
intervals are the same, the QT interval of the
subsequent beat may diﬀer if QT intervals of the
preceding beats vary. Moreover, alteration of auto-
nomic nervous system tone in response to changes in
heart rate may also contribute to modulation of the
QT interval. It has been demonstrated that sympa-
thetic stimulation will activate IKs and shorten the
action potential duration, potentially counteracting
the eﬀect of K channel blockers.25) If such tone can
change during AF, the RR and QT relationship may
also be variable. Furthermore, the proﬁle of QT-RR
hysteresis, i.e., the speed with which the QT interval
adapts to heart rate changes, is considered to be
highly individual with intrasubject stability and
intersubject variability.26)
To make matters more complicated, this relation-
ship between the QT and the preceding RR intervals
varies signiﬁcantly once AF is converted into sinus
rhythm (Figure 8). An important ﬁnding of exagger-
ated QT prolongation after cardioversion of AF
has been reported by Choy et al27) In their study,
dofetilide has been shown to cause only minor QT
prolongation during AF, but signiﬁcantly more QT
prolongation when given to the same patients after
cardioversion to sinus rhythm. Their data indicates
that the QT response to dofetilide in AF does not
predict the response after restoration to sinus rhythm,
and that exaggerated QT response may occur in
predisposed individuals. Furthermore, Darbar et al
have also demonstrated that cardioversion of AF
acutely increases the QT interval and the steepness of
the QT-RR slope which was seen in subjects taking
sotalol or quinidine but not amiodarone or ﬂecai-
nide28) (Figure 9). Interestingly, in accordance with
these observations, it has been demonstrated that
persistent AF is associated with reduced risk of TdP
in patients with drug-induced long QT syndrome.29)
Based on these observations, one should accept
that the RR and QT relationship is not ﬁxed but
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Figure 6 QT (A) and RR (B) intervals
preceding the onset of ventricular arrhyth-
mias in the same patient as in Figure 5.
(Adopted from 24)
The ECG recordings for the six circled com-
plexes in A and B are shown in C, aligned by the
R wave. The terminal portions of the T waves
for these complexes are shown in D at an
expanded time scale. The asterisks indicate the
ﬁducial point on the T wave for the QT
measurements.
The QT interval increased progressively, result-
ing in a premature ventricular complex (record-
ing 6). Note that RR intervals 2 and 3 were
similar, as were RR intervals 4 and 5, yet the
corresponding QT intervals diﬀered.
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rather dynamic. Accordingly, the corrected QT
interval or QTc interval which is considered to
reﬂect this relationship, is also a vulnerable param-
eter. Although the QTc interval has long been
advocated as a guide to predict development of
TdP,30) it needs to be reconsidered, particularly in the
setting of AF. Characteristically, the QTc interval
during AF is not only diﬃcult to measure, but even if
it is measured properly and calculated by a variety of
formulas, it can still vary within a short time period
and thus is an inappropriate, sometimes misleading
parameter in predicting the risk of TdP in patients
receiving K channel blockers.31) Furtheore, both the
Bazett and Fridericia correction formulas are re-
ported to overestimate the change in QT interval at
heart rates from 60 to 120 bpm or higher32) while
underestimating it at heart rates below 60 bpm. A
recent AHA/ACCF statement indicated that the QTc
interval longer than 500msec is a proarrhythmic
marker.30) If the Bazett formula is inappropriately
applied, a QT duration of 612msec could become
the longest acceptable interval for a beat preceded by
the RR interval of 1.5 sec during AF, which is
apparently misleading and even dangerous. The
application of these formulas to AF or sinus rhythm
with frequent ectopic beats as well as extreme
bradycardia or tachycardia should be avoided or
should require extreme caution. It should be remem-
bered that early depolarization develops at the
critical action potential duration (Figure 1), or at the
critical QT interval on the surface electrocardiogram
(Figure 6), and never develops at the critical ‘‘cor-
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Figure 7 Relation between the QT and RR intervals for
the periods of sinus rhythm separating the seven episodes
of ventricular arrhythmias shown in Figure 6 (Adopted
from 24)
The QT/RR relations are shown for the last 10 intervals
preceding episodes of ventricular arrhythmias (late [QTl and
RRl]) and for the remaining intervals (early [QTe and RRe]).
There was an upward shift of the QT interval for a given RR
interval preceding the onset of ventricular arrhythmias. The
upward shift of the QT interval was greater for short RR
intervals than for long RR intervals.
Figure 8 A marked QT prolongation
(0.68 sec) was exposed after AF was con-
verted to sinus rhythm (SR)
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rected QT interval’’. The QTc interval, as a matter of
fact, is just a marker for abnormal rate adaptation of
the QT interval, which can be diagnostic of genetic
long QT syndrome. This corrected interval would be
more appropriately used for the purpose of screening
the patient in sinus rhythm for such hereditary
abnormalities susceptible to K channel blockers.
Monitoring QT intervals, practical considera-
tions
As repeatedly stressed, the QT interval rather than
the QTc interval should be monitored during the
treatment with K channel blockers, particularly in
the presence of AF. For treatment of AF with K
channel blockers, the longest QT interval, not the
average QT interval should be sought in an electro-
cardiogram since the longest but not the average QT
interval is the one most closely linked to the
development of TdP.
The technical approaches to measuring QT inter-
vals or analyzing the QT morphology have been
discussed elsewhere and are not the subject of this
review.18,33–35) In routine clinical practice, QT
intervals are measured visually and manually, which
can be approximated to a 0.04 sec level of accuracy.
Unfortunately, there is no established threshold
below which prolongation of the QT interval is
considered free of proarrhythmic risk, and no clear-
cut consensus on the degree of drug-induced QT
prolongation that should require drug discontinua-
tion. Based on previously reported data, this author
would like to suggest the following guidelines,
which can be applied to patients with or without
AF. Whenever the longest QT interval exceeds
0.52 sec, the prescribing doctor should be alerted that
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Figure 9 QT-RR interval relationship in AF (top) and in sinus rhythm (bottom) for subjects
taking sotalol or quinidine (circle) and those taking amiodarone or ﬂecainide (square) (Adopted
from 28)
Predicted lines according to the Bazett (QTc=QT/RR^(1/2)) or Friedricia (QTc=QT/RR^(1/3))
formulae are also shown for reference.
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TdP is impending. Once the interval exceeds
0.56 sec, the dose should either be withheld or
decreased to bring back the interval below this level.
Importantly, when the QT interval of any single beat
exceeds 0.60 sec, the risk of developing TdP is
so high that not only should the culprit drug be
discontinued, but the patient is advised to be
hospitalized and placed under continuous electro-
cardiographic monitoring.
The management toward prevention of TdP in a
particular patient is continuous and laborious. Both
before and during the treatment with K channel
blockers, one is advised to conﬁrm whether any of
the risk factors discussed earlier with alphabet
acronyms (Table 1) exist that can modify the eﬀect
of the drugs. It may be helpful to measure the QTc
interval before prescribing a K channel blocker only
if there is sinus rhythm. If it is abnormally prolonged
from the beginning, the patient may have a reduced
repolarization reserve and genetic predisposition to
drug-induced TdP,36) and the administration of such
a drug should be discouraged. Once the drug has
been started, one should always keep in mind that the
QT interval is not ﬁxed, but varies constantly second
by second, hour by hour, day by day, and year by
year. The initial loading or titration period of drug
administration requires particular caution. In one
study comprising 120 patients with atrial arrhyth-
mias, Chung et al have demonstrated that new or
increased ventricular arrhythmias developed in 7
patients at 2:9 1:8 days after initiation of sotalol.37)
They recommended hospital admission and at least
72 hours of monitoring for initiation of sotalol. In
other drugs such as bepridil, it takes longer before
the plateau of the QT prolongation is reached, thus
frequent visits to an outpatient clinic or use of
transtelephonic monitoring instead of in-hospital
monitoring would be acceptable. Even after the peak
of QT prolongation has been reached, it is recom-
mended to take occasional 24 hour Holter monitor-
ing, particularly for patients with AF.
The QT interval should be measured whenever
any events occur that modify the action potential
duration. For example, when diarrhea occurs and
hypopotassemia develops, it can be expected that the
QT interval should be prolonged further even in the
presence of the same dose of K channel blockers. Or
when a patient visits another doctor for another
disease to receive other drugs with variable degrees
of K channel blocking action, the QT interval should
be monitored intensively. As described earlier, when
persistent AF has been converted to sinus rhythm,
one should measure the QT interval as soon as
possible.
AF sometimes facilitates the development or
progression of heart failure, while the latter can
increase the risk for the development of AF. With or
without AF, however, if a patient is taking K channel
blockers, it happens that TdP occasionally develops
after aggressive treatment of heart failure. Hypopo-
tassemia is often induced by diuretics. The heart rate
usually slows down during the recovery phase of
heart failure, which may unmask bradycardia-de-
pendent QT prolongation. The increased neurohu-
moral compensatory mechanism at the peak of acute
heart failure may be inactivated during convales-
cence, which could also unmask background QT
prolongation. On top of these vulnerable parameters,
diseased ventricular myocardial cells suﬀering left
ventricular failure characteristically have been
known to exhibit prolonged action potential dura-
tions.14) All these factors in concert prolong QT
interval signiﬁcantly, predisposing to TdP when the
patient is about to get out of the nightmare of
dyspnea.
The approach to coping with this moving target is
analogous to the control of INR during warfarin
administration for patients with AF. It takes days to
weeks to achieve the therapeutic plateau. Therefore,
frequent measurements of the QT interval are
suggested particularly during the initial titration
period. As INR has to be adjusted to a level that is
not too high to cause bleeding and not too low to
cause cerebral embolism, the QT interval has to be
adjusted somewhere between the extremes. As INR
changes frequently despite keeping the same dose
of warfarin, the QT interval also ﬂuctuates easily
despite taking the same dose of a K channel blocker.
Accordingly, the QT interval should be measured
routinely, as with INR, every time AF patients taking
these agents visit the clinic. Both INR and the QT
interval are vulnerable to drug-to-drug interaction, so
that caution should be advised against taking new
drugs without conﬁrming the safety of the combina-
tion, particularly when those drugs are to be
prescribed by independent doctors. Just like INR,
repeated measurements of the QT interval are
required every time a new drug has been added.
And just as INR is measured at the time of a bleeding
event, the measurement of the QT interval is a must
when a patient taking K channel blockers develops
syncope or presyncope.
Interestingly, the administration of warfarin is
recommended both before and after conversion of
persistent AF is attempted. Thus it is not uncommon
for both K channel blockers and warfarin to be
prescribed together to the same patient. It would be
helpful in such a situation to remember an old saying
Mitamura H Prevention of TdP during AF therapy
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that all drugs are poisons with some beneﬁcial side
eﬀects. Every doctor prescribing drugs to patients
should be aware of this proverb, which is particularly
true during the treatment of AF with K channel
blockers and warfarin.
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